Table 2. SARS-CoV-2 Infection and Vaccination Characteristics in Vaccinated Patients.
| Characteristic | Cohort, No. (%) | |
|---|---|---|
| Vienna | Meran | |
| No. | 24 | 484 |
| Verified SARS-CoV-2 infections | 2 (4.5) | 38 (7.9) |
| Positive anti-NC antibodiesa | 2 (4.5) | 42 (9.1) |
| Used vaccine | ||
| BNT162b2 | 14 (58.3) | 484 (100) |
| mRNA-1273 | 6 (25.0) | NA |
| AZD1222 | 4 (16.7) | NA |
| No. of received doses at time of sampling | ||
| 1 (partially vaccinated) | 15 (62.5) | 484 (100)b |
| 2 (fully vaccinated) | 9 (37.5) | 125 (25.8)b |
Abbreviations: anti-NC, anti–SARS-CoV-2 nucleocapsid; AZD1222, AstraZeneca; BNT162b2, BioNTech/Pfizer; mRNA-1273, Moderna; NA, not applicable.
a
Available in 462 of 484 patients (95.5%) in the Meran cohort.
b
Sampling after 1 dose was available in all patients in the Meran cohort, whereas sampling after 2 doses was performed in patients with anti-S levels less than 50 AU/mL after the first vaccination.